RATIONALE: Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood. OBJECTIVES: To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite, is involved in increased food intake and weight gain during treatment with antipsychotics. METHODS: Serum ghrelin concentrations were investigated in schizophrenic patients receiving olanzapine or risperidone, and in healthy volunteers. RESULTS: Serum ghrelin concentrations did not increase, but rather decreased, in patients treated with olanzapine or risperidone in comparison with healthy volunteers. No significant difference was found in serum ghrelin concentration between patients treated with olanzapine and risperidone. CONCLUSIONS: Our results indicate that ghrelin is not a direct cause of increased food intake and weight gain during treatment with olanzapine or risperidone, whereas ghrelin is associated with metabolic change in patients receiving these agents.
RATIONALE: Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood. OBJECTIVES: To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite, is involved in increased food intake and weight gain during treatment with antipsychotics. METHODS: Serum ghrelin concentrations were investigated in schizophrenicpatients receiving olanzapine or risperidone, and in healthy volunteers. RESULTS: Serum ghrelin concentrations did not increase, but rather decreased, in patients treated with olanzapine or risperidone in comparison with healthy volunteers. No significant difference was found in serum ghrelin concentration between patients treated with olanzapine and risperidone. CONCLUSIONS: Our results indicate that ghrelin is not a direct cause of increased food intake and weight gain during treatment with olanzapine or risperidone, whereas ghrelin is associated with metabolic change in patients receiving these agents.
Authors: D B Allison; J L Mentore; M Heo; L P Chandler; J C Cappelleri; M C Infante; P J Weiden Journal: Am J Psychiatry Date: 1999-11 Impact factor: 18.112
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: A E Rigamonti; A I Pincelli; B Corrà; R Viarengo; S M Bonomo; D Galimberti; M Scacchi; E Scarpini; F Cavagnini; E E Müller Journal: J Endocrinol Date: 2002-10 Impact factor: 4.286
Authors: M Matsumoto; H Hosoda; Y Kitajima; N Morozumi; Y Minamitake; S Tanaka; H Matsuo; M Kojima; Y Hayashi; K Kangawa Journal: Biochem Biophys Res Commun Date: 2001-09-14 Impact factor: 3.575
Authors: F M Theisen; S Gebhardt; T Brömel; B Otto; W Heldwein; M Heinzel-Gutenbrunner; J-C Krieg; H Remschmidt; M Tschöp; J Hebebrand Journal: J Neural Transm (Vienna) Date: 2005-06-15 Impact factor: 3.575
Authors: Milind V Masule; Sumit Rathod; Yogeeta Agrawal; Chandragouda R Patil; Kartik T Nakhate; Shreesh Ojha; Sameer N Goyal; Umesh B Mahajan Journal: Curr Res Pharmacol Drug Discov Date: 2022-06-13
Authors: Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles B Nemeroff; Georges Gharabawi; Ramy Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman Journal: J Psychiatr Res Date: 2008-02-25 Impact factor: 4.791
Authors: Vance L Albaugh; Cathy R Henry; Nicholas T Bello; Andras Hajnal; Susan L Lynch; Beth Halle; Christopher J Lynch Journal: Obesity (Silver Spring) Date: 2006-01 Impact factor: 5.002
Authors: Andreas Baranyi; Renè Yazdani; Alexandra Haas-Krammer; Alexandra Stepan; Hans-Peter Kapfhammer; Hans-Bernd Rothenhäusler Journal: Wien Med Wochenschr Date: 2007